comprehensive -WSS

comprehensive

author：focus 2025-08-12 08:25:49 - browse：347

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： MultiPlan and major insurers sued for alleged medical price

WSS

More tobacco lobbyists active in statehouses

Adults seen as increasingly susceptible to measles

Getting Alzheimer's drug Leqembi to patients can be a challenge

Cancer researcher Catriona Jamieson is sending tumors into space

Cholera vaccine supply gets boost as demand surges globally

Health care needs a new profession: neuroimaging counseling

Wikipedia

comprehensive

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Q&A: Jennifer Adair on making gene therapy available globally

In Memoriam: Notable people who died in 2023

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Why does health care cost so much? A reading guide

ChatGPT in medicine: STAT answers readers' burning questions

Physician groups backed by private equity giant lobby on mergers

As demand for Covid shots wanes, Moderna seeks its next success

MassMutual is introducing free genetic testing for members

focus

EQRx, failed developer of low

Cell therapy fails to slow type 1 diabetes, but safety is established

Scientists inch closer to single

Scientists inch closer to single

Cue Health's Covid

Q&A: Jennifer Adair on making gene therapy available globally

knowledge

focus

hotspot

leisure time